马兜铃酸及马兜铃科中药临床使用风险差异研究  

Risk difference between aristolochic acid and clinical use of traditional Chinese medicines in aristolochiaceae

作　　者：朱文静 张立丹 周玥 雷海民[2] ZHU Wenjing;ZHANG Lidan;ZHOU Yue;LEI Haimin(Certification Center for Licensed Pharmacist of National Medical Products Administration,Beijing 100061,China;Institute of Regulatory Science for Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100024,China)

机构地区：[1]国家药品监督管理局执业药师资格认证中心,北京100061 [2]北京中医药大学国家中药监管科学研究院,北京100102

出　　处：《中国药物警戒》2022年第11期1213-1217,共5页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(81603256);国家药品监督管理局委托课题(NMPA 2019-2020);中央高校基金科研业务项目(2020-JYB-ZDGG-044、2019-JYB-TD005)。

摘　　要：目的 梳理马兜铃酸毒性与马兜铃科中药的差异,为有毒中药临床合理使用提供借鉴和参考,避免公众混淆。方法 通过文献调研,回顾含马兜铃酸制品引发的安全用药问题,梳理含马兜铃酸中药的使用风险,同时总结既往马兜铃酸减毒研究。结果 马兜铃酸问题与马兜铃科中药两者本质不同,遵循中医药理论指导,临床合理使用含马兜铃科中药,不会引起严重不良反应。结论 建议提高我国有毒中药的科学监管能力和水平,避免盲目的中医药毒性或安全性质疑,为中药行业发展注入积极力量。Objective To study the difference between aristolochic acid toxicity and Aristolochiaceae in order to provide reference for rational use of toxic traditional Chinese medicines(TCM) and prevent confusion. Methods A series of problems with safe medication caused by aristolochic acid products was retrospectively analyzed through literature review.The risks of using Aristolochiaceae were summarized, and previous studies on aristolochic acid reduction were outlined.Results The problems caused by aristolochic acids were essentially different from those by Aristolochiaceae. Compliance with theories of TCM and rational use of Aristolochiaceae will not cause serious adverse reactions. Conclusion More rigorous supervision of toxic TCM are recommended. Irrational fears about the toxicity of TCM should be eliminated so as to boost the development of TCM industry.

关 键 词：马兜铃酸 马兜铃科 减毒 科学监管 

分 类 号：R969.3[医药卫生—药理学] R994.11[医药卫生—药学]